| Trial ID: | L2288 |
| Source ID: | NCT00328965
|
| Associated Drug: |
Lacidipine
|
| Title: |
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Essential Hypertension
|
| Interventions: |
DRUG: Lacidipine
|
| Outcome Measures: |
Primary: To investigate the clinical effectiveness of lacidipine on elevated systolic blood pressure (SBP) in Korean patients aged 35 to 75 years., 12 weeks from baseline | Secondary: To investigate the clinical effectiveness of lacidipine on elevated diastolic blood pressure and endothelial function by flow-medicated vasodilation and measurement of markers of inflammation in Korean patients aged 35 to 75 years with type 2 diabetes., 12 weeks from baseline
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-11
|
| Completion Date: |
2006-05
|
| Results First Posted: |
|
| Last Update Posted: |
2010-08-16
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00328965
|
